Although there are many potential mechanisms for development of clinical resistance, most cases of imatinib-resistant CML are due to point mutations in the BCR-ABL kinase domain itself, including T315I [10,11]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.